Abstract

Objective We identified differentially expressed microRNAs (DEMs) between esophageal carcinoma (ESCA) tissues and normal esophageal tissues. We then constructed a novel three-miRNA signature to predict the prognosis of ESCA patients using bioinformatics analysis. Materials and Methods. We combined two microarray profiling datasets from the Gene Expression Omnibus (GEO) database and RNA-seq datasets from the Cancer Genome Atlas (TCGA) database to analyze DEMs in ESCA. The clinical data from 168 ESCA patients were selected from the TCGA database to assess the prognostic role of the DEMs. The TargetScan, miRDB, miRWalk, and DIANA websites were used to predict the miRNA target genes. Functional enrichment analysis was conducted using the Database for Annotation, Visualization, and Integrated Discovery (David), and protein-protein interaction (PPI) networks were obtained using the Search Tool for the Retrieval of Interacting Genes database (STRING). Results With cut-off criteria of P < 0.05 and |log2FC| > 1.0, 33 overlapping DEMs, including 27 upregulated and 6 downregulated miRNAs, were identified from GEO microarray datasets and TCGA RNA-seq count datasets. The Kaplan–Meier survival analysis indicated that a three-miRNA signature (miR-1301-3p, miR-431-5p, and miR-769-5p) was significantly associated with the overall survival of ESCA patients. The results of univariate and multivariate Cox regression analysis showed that the three-miRNA signature was a potential prognostic factor in ESCA. Furthermore, the gene functional enrichment analysis revealed that the target genes of the three miRNAs participate in various cancer-related pathways, including viral carcinogenesis, forkhead box O (FoxO), vascular endothelial growth factor (VEGF), human epidermal growth factor receptor 2 (ErbB2), and mammalian target of rapamycin (mTOR) signaling pathways. In the PPI network, three target genes (MAPK1, RB1, and CLTC) with a high degree of connectivity were selected as hub genes. Conclusions Our results revealed that a three-miRNA signature (miR-1301-3p, miR-431-5p, and miR-769-5p) is a potential novel prognostic biomarker for ESCA.

Highlights

  • Esophageal carcinoma (ESCA), including esophageal adenocarcinoma and esophageal squamous cell carcinoma, is characterized by aggressive malignant tumor formation [1]

  • It has been reported that dysregulated miRNAs could be a potential biomarker for tumor diagnosis [7]. erefore, significantly differentially expressed microRNAs (DEMs) in ESCA could be effective biomarkers for early diagnosis, therapeutic strategy selection, and prognosis of ESCA

  • A large sample size with detailed clinical features is important for reliable survival prediction in patients with ESCA. e Gene Expression Omnibus (GEO) database provides an invaluable resource for gene expression data and other functional genomics data [11]. e Cancer Genome Atlas (TCGA) project contains sequencing data on more than 11,000 miRNAs as well as clinical information from cancer patients [12]

Read more

Summary

Introduction

Esophageal carcinoma (ESCA), including esophageal adenocarcinoma and esophageal squamous cell carcinoma, is characterized by aggressive malignant tumor formation [1]. It is the eighth most common type of cancer and the sixth most frequent cause of cancer-related death globally [2]. Erefore, significantly differentially expressed microRNAs (DEMs) in ESCA could be effective biomarkers for early diagnosis, therapeutic strategy selection, and prognosis of ESCA. Previous studies have reported that a number of DEMs are associated with ESCA prognosis [8,9,10] These studies had limitations including clinical heterogeneity, BioMed Research International sample insufficiency, and differences in various data processing methods. A large sample size with detailed clinical features is important for reliable survival prediction in patients with ESCA. e Gene Expression Omnibus (GEO) database provides an invaluable resource for gene expression data and other functional genomics data [11]. e Cancer Genome Atlas (TCGA) project contains sequencing data on more than 11,000 miRNAs as well as clinical information from cancer patients [12]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call